Danny Tomka Forest Laboratories FRX-N TOP PICK Nov 09, 2004

Stock price has been cut in half since March/04 because of their depression drug which is coming off patent. Creating their own generic drug. Great company. Juggernaut sales force. Has about $4 of cash. Has a product ramp in alzheimers.

Danny Tomka

Owned

Unlock Rating

$43.510

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

Buy, stick away and don't look at it for quite awhile. Costs are low on R & D because they tend to buy compounds that have already been researched. Not cheap.

TOP PICK

Had dropped because of concerns about teens using their anti-depressant. A good price.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Danny Tomka Forest Laboratories FRX-N TOP PICK Nov 09, 2004

You might be interested:

Forest Laboratories(FRX-N)

Forest Laboratories(FRX-N)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights